S&P 및 Nasdaq 내재가치 문의하기

Bone Biologics Corporation BBLG NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Bone Biologics Corporation (BBLG) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.

애널리스트 추정 주당순이익(EPS) $-19.02 및 매출 $0.00B 다음 회계연도.

주당순이익(EPS) 실적 추이: 2024: 실적 $-4.83 vs 추정 $-19.02 (상회 +74.6%). 2025: 실적 $-2.65 vs 추정 $-2.36 (하회 -12.3%). 애널리스트 정확도: 0%.

EPS 전망 — BBLG

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$4.83 vs Est –$19.02 ▲ 293.8% off
2025 Actual –$2.65 vs Est –$2.36 ▼ 10.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

매출 전망 — BBLG

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
문의하기
🎓
SharesGrow 아카데미
내재가치 계산법과 저평가 종목 찾기를 배우세요.
주간 라이브 세션
메시지 보내기